DOC, an Italian pharmaceutical company active in the market of branded and equivalent products, announced the agreement for the acquisition of Muscoril, a drug with a muscle relaxant action, marketed by Sanofi, for Italy, Portugal and the Czech Republic.
The transaction, supported by the shareholders of DOC, TPG and ICG, will further strengthen DOC’s position in the market, confirming the company’s commitment to improving health through effective and accessible treatments. Muscoril will also increase DOC’s existing product line, already packed with over 250 molecules in various therapeutic areas and approximately 700 SKUs covering all major therapeutic areas.
The signing of this agreement represents an important step forward for DOC in our expansion journey into the Italian market. Muscoril not only enhances our current portfolio, but aligns perfectly with our growth strategy in both the branded and co-branded markets. Operations like this allow us to build a solid and resilient platform, capable of supporting our future growth.
Riccardo Zagaria, DOC Ceo
Karthic Jayaraman, partner at TPG, added: “Signing the Muscoril acquisition demonstrates DOC’s ability to recognize valuable assets and create an integrated platform to improve care through access to essential, high-quality treatments . This transaction will strengthen DOC’s role as a trusted partner for doctors, pharmacists and patients. We are proud to support the company in its continued expansion.”
Thanks to its proven effectiveness, Muscoril has established itself as one of the leading brands among muscle relaxant drugs in Italy. The product is available in different pharmaceutical forms, including orodispersible tablets, capsules and injectable solutions, thus offering patients different treatment options.
